Abstract
ABSTRACT Background We recently demonstrated that the vitamin A derivative etretinate was clinically effective in the treatment of skin disorders in patients with systemic sclerosis (SSc). The aim of the present study is to investigate whether the oral treatment with etretinate improves sclerosis in bleomycin (BLM)-induced sclerotic skin mice. Methods BLM-induced sclerotic skin mice were treated orally with 10 mg/kg etretinate for 1 to 28 days. One control group received only the vehicle, 50 μl peanut oil, while another group received no agents. BLM-treated skin was removed and dermal thickness was measured histologically. Histopathological observation and TUNEL assay were also studied. Messenger RNA (mRNA) ratios for procollagen α 1 (I) chain to β actin from etretinate-treated and control mice were quantified at 1, 6, 14, and 28 days post-treatment, using quantitative RT-PCRs. Results There was a significant decrease in mean dermal thickness ( P P P Conclusions Etretinate improved BLM-induced scleroderma. These results suggest that etretinate can be applied to the treatment of SSc skin disorders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
